Cryptotanshinone reverses the epithelial-mesenchymal transformation process and attenuates bleomycin-induced pulmonary fibrosis.


Journal

Phytotherapy research : PTR
ISSN: 1099-1573
Titre abrégé: Phytother Res
Pays: England
ID NLM: 8904486

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 30 12 2019
revised: 13 03 2020
accepted: 25 03 2020
pubmed: 14 4 2020
medline: 1 12 2020
entrez: 14 4 2020
Statut: ppublish

Résumé

Idiopathic pulmonary fibrosis (IPF) is a fibrotic interstitial pneumonia that causes pulmonary tissue damage and functional impairment. To investigate the effects of cryptotanshinone on pulmonary fibrosis, the expression of NIH/3T3, HPF, and rat primary pulmonary fibroblasts was measured and found to be inhibited by CPT in a time- and concentration-dependent manner, and the upregulation of α-SMA expression in NIH/3T3 and HPF cells, which had been stimulated by TGFβ-1, was decreased after CPT administration. We observed that CPT could reverse the increase in α-SMA expression and vimentin and the decrease in E-cad expression in A549 cells, which had been induced by 5 ng/mL TGFβ-1, indicating that CPT has inhibitory effects in the EMT process. A BLM-induced pulmonary fibrosis model was established in C57BL/6 mice. The lung coefficient and hydroxyproline content increased significantly in the BLM-induced group and were decreased in the CPT-treated group. The expression levels of collagen-I and α-SMA and the phosphorylation level of Stat3 were significantly increased, and CPT treatment decreased these levels. Furthermore, the results from the flow cytometry analysis indicated that, in lung tissues, the frequencies of MDSCs, macrophages, DCs and T cells were considerably increased in the BLM-induced group, while CPT treatment reduced these immunocyte populations.

Identifiants

pubmed: 32281701
doi: 10.1002/ptr.6699
doi:

Substances chimiques

Antibiotics, Antineoplastic 0
Drugs, Chinese Herbal 0
Phenanthrenes 0
Bleomycin 11056-06-7
cryptotanshinone 5E9SXT166N

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2685-2696

Subventions

Organisme : National Natural Science Foundation of China
ID : 81500054
Organisme : Sichuan University
ID : 2018YJSY110

Informations de copyright

© 2020 John Wiley & Sons, Ltd.

Références

Afik, R., Zigmond, E., Vugman, M., Klepfish, M., Shimshoni, E., Pasmanik-Chor, M., … Varol, C. (2016). Tumor macrophages are pivotal constructors of tumor collagenous matrix. Journal of Experimental Medicine, 213(11), 2315-2331.
Bargagli, E., Masi, M. D., Perruzza, M., Vietri, L., Bergantini, L., Torricelli, E., …Lavorini, F. (2019). The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis. Internal and Emergency Medicine, 14(1), 39-43.
Darryl, K., Mutsaers, S. E., & Prêle, C. M. (2011). STAT3 in tissue fibrosis: Is there a role in the lung? Pulmonary Pharmacology & Therapeutics, 24(2), 193-198.
Haiying, T., Huanyu, H., Hong, J., Lili, G., Jingwei, M., Jia, L., …Taihua, W. (2015). Tanshinone IIA ameliorates bleomycin-induced pulmonary fibrosis and inhibits transforming growth factor-beta-β-dependent epithelial to mesenchymal transition. Journal of Surgical Research, 197(1), 167-175.
He, H., Tang, H., Gao, L., Wu, Y., Feng, Z., Lin, H.,& Wu, T. (2015). Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis in rats. Molecular Medicine Reports, 11(6), 4190-4196.
Hillary, L. K., Flaherty, K. R., & Moore, B. B. (2013). Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Current Opinion in Pharmacology, 13(3), 377-385.
Huang, S., Chen, W. (2014). Cryptotanshinone. In: Schwab M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg.
Imran, K. M., Rahman, N., Yoon, D., Jeon, M., Lee, B. T., & Kim, Y. S. (2017). Cryptotanshinone promotes commitment to the brown adipocyte lineage and mitochondrial biogenesis in C3H10T1/2 mesenchymal stem cells via AMPK and p38-MAPK signaling. Molecular and Cell Biology of Lipids, 1862(10-part A), 1110-1120.
Kyung, S. Y., Kim, D. Y., Yoon, J. Y., Son, E. S., Kim, Y. J., Park, J. W., & Jeong, S. H. (2018). Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition. BMC Pharmacology and Toxicology, 19(1), 13.
Lancet, T. (2015). New guidelines for idiopathic pulmonary fibrosis. Lancet, 386(9991), e3-e19.
Lebrun, A., Lo Re, S., Chantry, M., Izquierdo Carerra, X., Uwambayinema, F., Ricci, D., …Huaux, F. (2017). CCR2+ monocytic myeloid-derived suppressor cells (M-MDSCs) inhibit collagen degradation and promote lung fibrosis by producing transforming growth factor-β1. Journal of Pathology, 243(3), 320-330.
Li, Y., Shi, S., Gao, J., Han, S., Wu, X., Jia, Y., … Hu, D. (2016). Cryptotanshinone downregulates the profibrotic activities of hypertrophic scar fibroblasts and accelerates wound healing: A potential therapy for the reduction of skin scarring. Biomedicine & Pharmacotherapy, 80, 80-86.
Lipscomb, M. F., & Masten, B. J. (2002). Dendritic cells: Immune regulators in health and disease. Physiological Reviews, 82(1), 97-130.
Liu, S., Han, Z., Trivett, A. L., Lin, H., Hannifin, S., Yang, D.,… Oppenheim, J. J. (2019). Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma. Cancer Immunology, Immunotherapy, 68(7), 1059-1071.
Liucheng, L., Delin, L., Liang, X., Ping, Z., Ziyu, D., Xiaoting, M., …Jian, G. (2015). Total extract of Yupingfeng attenuates bleomycin-induced pulmonary fibrosis in rats. Phytomedicine, 22(1), 111-119.
Lo, S. H., Hsu, C. T., Niu, H. S., Niu, C. S., Cheng, J. T., & Chen, Z. C. (2017). Cryptotanshinone inhibits STAT3 signaling to alleviate cardiac fibrosis in type 1-like diabetic rats. Phytotherapy Research, 31(4), 638-646.
Ma, J., Bishoff, B., Mercer, R. R., Barger, M., Schwegler-Berry, D., & Castranova, V. (2017). Role of epithelial-mesenchymal transition (EMT) and fibroblast function in cerium oxide nanoparticles-induced lung fibrosis. Toxicology & Applied Pharmacology, 323, 16-25.
Maione, F., Piccolo, M., Vita, S. D., Chini, M. G., Cristiano, C., Caro, C. D., …Bifulco, G. (2017). Down regulation of pro-inflammatory pathways by tanshinone IIA and cryptotanshinone in a non-genetic mouse model of Alzheimer's disease. Pharmacological Research, 129, 482-490.
Marchal-Sommé, J., Uzunhan, Y., Marchand-Adam, S., Kambouchner, M., Valeyre, D., Crestani, B., & Soler, P. (2007). Dendritic cells accumulate in human fibrotic interstitial lung disease. American Journal of Respiratory & Critical Care Medicine, 176(10), 1007-1014.
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., … Wells, A. U. (2017). Idiopathic pulmonary fibrosis. Nature Reviews Disease Primers, 3, 17074.
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Du Bois, R. M., Fagan, E. A., …King, T. E, J. (2016). Pirfenidone for idiopathic pulmonary fibrosis: Analysis of pooled data from three multinational phase 3 trials. European Respiratory Journal, 47(1), 243-253.
Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012). Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Paper presented at the Seminars in cancer biology, Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.
Papiris, S. A., Kollintza, A., Kitsanta, P., Kapotsis, G., Karatza, M., Milicemili, J., …Daniil, Z. (2005). Relationship of BAL and lung tissue CD4+ and CD8+ T lymphocytes, and their ratio in idiopathic pulmonary fibrosis. Chest, 128(4), 2971-2977.
Qian, H., Lin, L., Zhao, B., Wang, N., & Liu, X. (2018). Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition. Biochemical & Biophysical Research Communications, 500(4), 839-845.
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., … ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. (2011). An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine, 183(6), 788-824.
Richeldi, L., Cottin, V., du Bois, R. M., Selman, M., Kimura, T., Bailes, Z., … Brown, K. K. (2016). Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials. Respiratory Medicine, 113, 74-79.
Shu, T., Shen, X. Y., Huang, H. Q., Xu, S. W., Yang, Y., Zhou, C. H., …Peiqing, L. (2011). Cryptotanshinone suppressed inflammatory cytokines secretion in RAW264.7 macrophages through inhibition of the NF-κB and MAPK signaling pathways. Inflammation, 34(2), 111-118.
Sibinska, Z., Tian, X., Korfei, M., Kojonazarov, B., Kolb, J. S., Klepetko, W., … Schermuly, R. T. (2017). Amplified canonical transforming growth factor-β signalling via heat shock protein 90 in pulmonary fibrosis. European Respiratory Journal, 49(2), 1501941.
Sriram, N., Kalayarasan, S., Manikandan, R., Arumugam, M., & Sudhandiran, G. (2015). Epigallocatechin gallate attenuates fibroblast proliferation and excessive collagen production by effectively intervening TGF-β1 signalling. Clinical & Experimental Pharmacology & Physiology, 42(8), 849-859.
Tang, Y., Chen, Y., Chu, Z., Yan, B., & Xu, L. (2014). Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice. European Journal of Pharmacology, 723(1), 494-500.
Wang, W., Wang, X., Zhang, X. S., & Liang, C. Z. (2018). Cryptotanshinone attenuates oxidative stress and inflammation through the regulation of Nrf-2 and NF-κB in mice with unilateral ureteral obstruction. Basic & Clinical Pharmacology & Toxicology, 123(6), 714-720.
Wang, W., Zhou, P.-H., Hu, W., Xu, C.-G., Zhou, X.-J., Liang, C.-Z., & Zhang, J. (2018). Cryptotanshinone hinders renal fibrosis and epithelial transdifferentiation in obstructive nephropathy by inhibiting TGF-β1/Smad3/integrin β1 signal. Oncotarget, 9(42), 26625-26637.
Wu, H., Li, Y., Wang, Y., Xu, D., Li, C., Liu, M., … Li, Z. (2014). Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis via modulating angiotensin-converting enzyme 2/ angiotensin-(1-7) axis in rats. International Journal of Medical Sciences, 11(6), 578-586.
Xaubet, A., Molina-Molina, M., Acosta, O., Bollo, E., Castillo, D., Fernández-Fabrellas, E., … Ancochea, J. (2017). Guidelines for the medical treatment of idiopathic pulmonary fibrosis. Archivos De Bronconeumologia, 53(5), 263-269.
Xu, H., Yang, F., Sun, Y., Yuan, Y., Cheng, H., Wei, Z., … Wang, R. (2012). A new Antifibrotic target of ac-SDKP: Inhibition of Myofibroblast differentiation in rat lung with silicosis. PLoS One, 7(7), e40301.
Yunzi, M., Hong, L., Zhongbao, Y., Jinlei, G., Suowen, X., Jian, X., …Peiqing, L. (2014). Cryptotanshinone attenuates cardiac fibrosis via downregulation of COX-2, NOX-2, and NOX-4. Journal of Cardiovascular Pharmacology, 64(1), 28-37.
Zhang, Z., Qu, J., Zheng, C., Zhang, P., Zhou, W., Cui, W., … Gao, J. (2018). Nrf2 antioxidant pathway suppresses numb-mediated epithelial-mesenchymal transition during pulmonary fibrosis. Cell Death & Disease, 9(2), 83.
Zhu, Z., Zhao, Y., Li, J., Tao, L., Shi, P., Wei, Z., … Lu, Y. (2016). Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-α mRNA via decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Molecular Carcinogenesis, 55(10), 1399-1410.

Auteurs

Qianyu Zhang (Q)

Department of Liver Surgery & Liver Transplantation, State Key of Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, People's Republic of China.
West China School of Public Health and Heathy Food Evaluation Research Center and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Cailing Gan (C)

Department of Liver Surgery & Liver Transplantation, State Key of Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, People's Republic of China.

Hongyao Liu (H)

Department of Liver Surgery & Liver Transplantation, State Key of Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, People's Republic of China.

Liqun Wang (L)

West China School of Public Health and Heathy Food Evaluation Research Center and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Yali Li (Y)

West China School of Public Health and Heathy Food Evaluation Research Center and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Zui Tan (Z)

Department of Liver Surgery & Liver Transplantation, State Key of Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, People's Republic of China.

Jia You (J)

West China School of Public Health and Heathy Food Evaluation Research Center and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Yuqin Yao (Y)

West China School of Public Health and Heathy Food Evaluation Research Center and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Yongmei Xie (Y)

Department of Liver Surgery & Liver Transplantation, State Key of Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, People's Republic of China.

Wenya Yin (W)

West China School of Public Health and Heathy Food Evaluation Research Center and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Tinghong Ye (T)

Department of Liver Surgery & Liver Transplantation, State Key of Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH